Andrew C Perkins

List of Publications by Year
in descending order

141 papers	7,510 citations	76326 40 h-index	54911 84 g-index
150 all docs	150 docs citations	150 times ranked	11283 citing authors

#	Article	IF	Citations
1	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discovery, 2022, 12, 1560-1579.	9.4	13
2	The Role of LNK (SH2B3) in the Regulation of JAK-STAT Signalling in Haematopoiesis. Pharmaceuticals, 2022, 15, 24.	3.8	11
3	Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. Pathology, 2022, , .	0.6	2
4	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	2.4	31
5	Myeloid somatic mutation panel testing in myeloproliferative neoplasms. Pathology, 2021, 53, 339-348.	0.6	13
6	BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).. Journal of Clinical Oncology, 2021, 39, TPS7057-TPS7057.	1.6	7
7	Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.. Journal of Clinical Oncology, 2021, 39, e19040-e19040.	1.6	0
8	Poster: MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S231.	0.4	0
9	Congenital Anemia Phenotypes Due to KLF1 Mutations. Journal of Pediatric Hematology/Oncology, 2021, 43, e148-e149.	0.6	3
10	Fragmentation of tissue-resident macrophages during isolation confounds analysis of single-cell preparations from mouse hematopoietic tissues. Cell Reports, 2021, 37, 110058.	6.4	36
11	Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy. Nature Communications, 2021, 12, 6546.	12.8	7
12	A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). Blood, 2021, 138, 2350-2350.	1.4	4
13	MPN-149: Long-Term Safety of Momelotinib in JAK Inhibitor-NaÃ¯ve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S330-S331.	0.4	0
14	The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. Blood, 2020, 136, 957-973.	1.4	35
15	Clinical acceleration of JAK2 p.V617F driven myeloproliferative disease due to a new uncommon homozygous MPL p.Y591D mutation. Haematologica, 2020, 105, e428-e431.	3.5	1
16	Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nature Communications, 2020, 11, 3021.	12.8	15
17	Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nature Communications, 2020, 11, 2042.	12.8	99
18	The effectiveness of a novel sleep clinical pathway in an inpatient musculoskeletal rehabilitation cohort: A pilot randomized controlled trial. Journal of Rehabilitation Medicine Clinical Communications, 2020, 3, 1000029.	0.6	0

#	Article	IF	Citations
19	Gene Editing of KLF1 to Cure Sickle Cell Disease. Blood, 2020, 136, 30-31.	1.4	5
20	KLF3 Represses the Inflammatory Response in Macrophages. Blood, 2020, 136, 36-36.	1.4	0
21	Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis. Blood, 2020, 136, 52-53.	1.4	2
22	NEW DIRECT TARGETS OF PSTAT3 AND PSTAT5 IN HUMAN ERYTHROID AND MEGAKARYOCYTIC CELLS. Experimental Hematology, 2019, 76, S72.	0.4	0
23	2000 - MONOLINEAGE ORIGIN OF RELAPSE FOLLOWING MULTILINEAGE DIFFERENTIATION THERAPY OF ACUTE MYELOID LEUKEMIA. Experimental Hematology, 2019, 76, S42.	0.4	0
24	SPECIFIC DOMAINS OF LNK (SH2B3) BIND AND REGULATE TPOR STABILITY AND SIGNALLING. Experimental Hematology, 2019, 76, S73.	0.4	0
25	Corrupted DNA-binding specificity and ectopic transcription underpin dominant neomorphic mutations in KLF/SP transcription factors. BMC Genomics, 2019, 20, 417.	2.8	18
26	Genetic Variants Within the Erythroid Transcription Factor, KLF1, and Reduction of the Expression of Lutheran and Other Blood Group Antigens: Review of the In(Lu) Phenotype. Transfusion Medicine Reviews, 2019, 33, 111-117.	2.0	6
27	HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDR. Blood Advances, 2019, 3, 406-418.	5.2	16
28	3173 â€“ AP2A2 KO MICE LINK FETAL LIVER HAEMATOPOIESIS EXHAUSTION TO LOSS OF HSC QUIESCENCE, PERTURBED ASYMMETRICAL FATE AND ALTERED LIPID METABOLISM. Experimental Hematology, 2019, 76, e4.	0.4	0
29	Recommendations for the use of pegylated interferonâ€Î± in the treatment of classical myeloproliferative neoplasms. Internal Medicine Journal, 2019, 49, 948-954.	0.8	7
30	KLF1 variants and the impact on the expression of red blood cell surface molecules in blood donors with the In(Lu) phenotype. Pathology, 2018, 50, S104.	0.6	0
31	Variable serologic and other phenotypes due to KLF1 mutations. Transfusion, 2018, 58, 1324-1325.	1.6	0
32	Self-Repopulating Recipient Bone Marrow Recipient Macrophages Promote Hematopoietic Stem Cell Engraftment Post Autologous Transplantation. Experimental Hematology, 2018, 64, S92-S93.	0.4	0
33	Investigation of the variable In(Lu) phenotype caused by KLF1 variants. Transfusion, 2018, 58, 2414-2420.	1.6	5
34	Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment. Blood, 2018, 132, 735-749.	1.4	69
35	JAK1 somatic mutation in myeloproliferative neoplasm. Pathology, 2018, 50, S104-S105.	0.6	0
36	CDX2 Expression in Hematopoietic Stem Cells Represents a Novel Model of De Novo Leukemia. Experimental Hematology, 2018, 64, S50-S51.	0.4	0

#	Article	IF	Citations
37	Mutant KLF1 in Adult Anemic Nan Mice Leads to Profound Transcriptome Changes and Disordered Erythropoiesis. Scientific Reports, 2018, 8, 12793.	3.3	14
38	EPO does not promote interaction between the erythropoietin and beta-common receptors. Scientific Reports, 2018, 8, 12457.	3.3	21
39	KLF1 Acts As a Pioneer Transcription Factor to Open Chromatin and Facilitate Recruitment of GATA1. Blood, 2018, 132, 501-501.	1.4	4
40	Vascular E-Selectin Acts As a Gatekeeper Inducing Commitment and Loss of Self-Renewal in HSC Transmigrating through the Marrow Vasculature. Blood, 2018, 132, 4552-4552.	1.4	0
41	Neomorphic effects of the neonatal anemia (Nan-Eklf) mutation contribute to deficits throughout development. Development (Cambridge), 2017, 144, 430-440.	2.5	19
42	A caseâ€based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. Internal Medicine Journal, 2017, 47, 262-268.	0.8	3
43	KrÃ¼ppel-like factors compete for promoters and enhancers to fine-tune transcription. Nucleic Acids Research, 2017, 45, 6572-6588.	14.5	40
44	Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nature Genetics, 2017, 49, 1025-1034.	21.4	148
45	JAK1 somatic mutation in a myeloproliferative neoplasm. Haematologica, 2017, 102, e324-e327.	3.5	9
46	Diagnosis in subdural myeloid sarcoma. Neuroradiology Journal, 2017, 30, 269-273.	1.2	3
47	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematology,the, 2017, 4, e225-e236.	4.6	224
48	High resolution temporal transcriptomics of mouse embryoid body development reveals complex expression dynamics of coding and noncoding loci. Scientific Reports, 2017, 7, 6731.	3.3	11
49	Direct targets of pSTAT5 signalling in erythropoiesis. PLoS ONE, 2017, 12, e0180922.	2.5	36
50	Promiscuous DNA-binding of a mutant zinc finger protein corrupts the transcriptome and diminishes cell viability. Nucleic Acids Research, 2017, 45, 1130-1143.	14.5	33
51	Impact of the c-MybE308G mutation on mouse myelopoiesis and dendritic cell development. PLoS ONE, 2017, 12, e0176345.	2.5	4
52	Fibroblast growth factor-1 (FGF-1) promotes adipogenesis by downregulation of carboxypeptidase A4 (CPA4) â€“ a negative regulator of adipogenesis implicated in the modulation of local and systemic insulin sensitivity. Growth Factors, 2016, 34, 210-216.	1.7	29
53	The Evx1/Evx1as gene locus regulates anterior-posterior patterning during gastrulation. Scientific Reports, 2016, 6, 26657.	3.3	24
54	KrÃ¼ppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. Blood, 2016, 127, 1856-1862.	1.4	124

#	Article	IF	Citations
55	Radio-resistant recipient bone marrow (BM) macrophages (MACS) are necessary for hematopoietic stem cell (HSC) engraftment post transplantation. Experimental Hematology, 2016, 44, S43-S44.	0.4	1
56	Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation. Journal of Molecular Diagnostics, 2016, 18, 707-718.	2.8	18
57	High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22. Scientific Reports, 2016, 6, 28990.	3.3	243
58	Relationship of JAK2V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF). Blood, 2016, 128, 3131-3131.	1.4	2
59	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.. Journal of Clinical Oncology, 2016, 34, 7011-7011.	1.6	1
60	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.. Journal of Clinical Oncology, 2016, 34, 7065-7065.	1.6	4
61	Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.. Journal of Clinical Oncology, 2016, 34, 7066-7066.	1.6	0
62	Fine-Tuning Erythropoiesis By Competition Between KrÃ¼ppel-like Factors for Promoters and Enhancers. Blood, 2016, 128, 1036-1036.	1.4	0
63	Identifying Novel Modifiers of Embryonic Globin Expression By Combining Chipseq, Rnaseq and eQTL Mapping in the Adult Nan Mouse Model. Blood, 2016, 128, 398-398.	1.4	0
64	Mutations in the Second Linker of KLF1 Cause Congenital Non-Spherocytic Hemolytic Anemia Due to Global Reduction of In Vivo DNA-Binding Affinity. Blood, 2016, 128, 1246-1246.	1.4	1
65	Direct Targets of Epo Receptor-JAK2-pSTAT5 Signalling in Erythropoiesis. Blood, 2016, 128, 3881-3881.	1.4	0
66	Autologous haematopoietic stem cell transplantation requires recipient BM macrophages. Experimental Hematology, 2015, 43, S71.	0.4	0
67	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 2015, 100, 479-488.	3.5	246
68	Macrophages and regulation of erythropoiesis. Current Opinion in Hematology, 2015, 22, 212-219.	2.5	49
69	KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. Blood, 2015, 125, 2405-2417.	1.4	87
70	Identification of novel hypomorphic and null mutations in Klf1 derived from a genetic screen for modifiers of Î±-globin transgene variegation. Genomics, 2015, 105, 116-122.	2.9	11
71	Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).. Journal of Clinical Oncology, 2015, 33, LBA7006-LBA7006.	1.6	10
72	Degenerate DNA Binding By Mutant (E339D) KLF1 Dramatically Alters the Erythroid Transcriptome in the Nan Mouse Model. Blood, 2015, 126, 932-932.	1.4	0

#	Article	IF	Citations
73	Characterisation of Novel Hypomorphic and Null Mutations in Klf1 Derived from a Genetic Screen for Modifiers of a-Globin Transgene Variegation. Blood, 2015, 126, 3329-3329.	1.4	0
74	A high-throughput screening strategy for detecting CRISPR-Cas9 induced mutations using next-generation sequencing. BMC Genomics, 2014, 15, 1002.	2.8	89
75	Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood, 2014, 123, 2682-2690.	1.4	103
76	Heme-bound iron activates placenta growth factor in erythroid cells via erythroid KrÃ¼ppel-like factor. Blood, 2014, 124, 946-954.	1.4	40
77	Mobilisation of Reconstituting HSC Is Boosted By Synergy Between G-CSF and E-Selectin Antagonist GMI-1271.. Blood, 2014, 124, 317-317.	1.4	2
78	KLF1 Null Neonates Display Hydrops Fetalis and a Deranged Erythroid Transcriptome. Blood, 2014, 124, 2700-2700.	1.4	0
79	New Insights into the Mechanism of Dominant Anemia Caused By Zinc Finger Mutations in KLF1. Blood, 2014, 124, 740-740.	1.4	0
80	Three fingers on the switch. Current Opinion in Hematology, 2013, 20, 193-200.	2.5	64
81	Generation of Mice Deficient in both KLF3/BKLF and KLF8 Reveals a Genetic Interaction and a Role for These Factors in Embryonic Globin Gene Silencing. Molecular and Cellular Biology, 2013, 33, 2976-2987.	2.3	38
82	Mutations In The Zinc Finger Domain Of Human and Mouse KLF1 Cause Congenital Dyserythropoietic Anemia (CDA) Via Promiscuous DNA Binding and Ectopic Target Gene Expression. Blood, 2013, 122, 11-11.	1.4	2
83	Rapid Molecular Diagnosis Of JAK2V617F Negative MPN By Targeted Deep Sequencing Using The Ion Torrent PGM. Blood, 2013, 122, 4093-4093.	1.4	0
84	Dynamics and Mechanics Of KLF1 Regulation In Erythropoiesis. Blood, 2013, 122, 2176-2176.	1.4	11
85	Placenta Growth Factor Is Regulated By Heme-Bound Iron Via Erythroid KrÃ¼ppel-Like Factor In Erythroid Cells and Is Linked To Iron Status In Vivo In Sickle Cell Disease and Hereditary Hemochromatosis. Blood, 2013, 122, 432-432.	1.4	0
86	The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. EMBO Journal, 2012, 31, 3309-3322.	7.8	32
87	Novel roles for KLF1 in erythropoiesis revealed by mRNA-seq. Genome Research, 2012, 22, 2385-2398.	5.5	82
88	The CACCC-Binding Protein KLF3/BKLF Represses a Subset of KLF1/EKLF Target Genes and Is Required for Proper Erythroid Maturation In Vivo. Molecular and Cellular Biology, 2012, 32, 3281-3292.	2.3	37
89	Prediction of novel long non-coding RNAs based on RNA-Seq data of mouse Klf1 knockout study. BMC Bioinformatics, 2012, 13, 331.	2.6	117
90	Interaction of c-Myb with p300 Is Required for the Induction of Acute Myeloid Leukemia by Human AML Oncogenes, and Represents a Potential Therapeutic Target.. Blood, 2012, 120, 2402-2402.	1.4	0

#	Article	IF	Citations
91	Macrophage Activation and Differentiation Signals Regulate Schlafen-4 Gene Expression: Evidence for Schlafen-4 as a Modulator of Myelopoiesis. PLoS ONE, 2011, 6, e15723.	2.5	67
92	Megakaryocyte-erythroid lineage promiscuity in EKLF null mouse blood. Haematologica, 2010, 95, 144-147.	3.5	35
93	A recessive screen for genes regulating hematopoietic stem cells. Blood, 2010, 116, 5849-5858.	1.4	27
94	KLF1 directly coordinates almost all aspects of terminal erythroid differentiation. IUBMB Life, 2010, 62, 886-890.	3.4	67
95	A global role for KLF1 in erythropoiesis revealed by ChIP-seq in primary erythroid cells. Genome Research, 2010, 20, 1052-1063.	5.5	180
96	EKLF/KLF1 Controls Cell Cycle Entry via Direct Regulation of E2f2. Journal of Biological Chemistry, 2009, 284, 20966-20974.	3.4	61
97	High-throughput chromatin information enables accurate tissue-specific prediction of transcription factor binding sites. Nucleic Acids Research, 2009, 37, 14-25.	14.5	57
98	Evolution of gene function and regulatory control after whole-genome duplication: Comparative analyses in vertebrates. Genome Research, 2009, 19, 1404-1418.	5.5	177
99	Complex architecture and regulated expression of the Sox2ot locus during vertebrate development. Rna, 2009, 15, 2013-2027.	3.5	200
100	Indian hedgehog supports definitive erythropoiesis. Blood Cells, Molecules, and Diseases, 2009, 43, 149-155.	1.4	23
101	A Recessive Embryonic Screen for Genes Regulating Hematopoietic Stem Cell and Blood Cell Generation and Function.. Blood, 2009, 114, 2527-2527.	1.4	0
102	Klf1 Regulatory Networks in Primary Erythroid Cells.. Blood, 2009, 114, 1462-1462.	1.4	0
103	Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nature Methods, 2008, 5, 613-619.	19.0	952
104	A mechanism for Ikaros regulation of human globin gene switching. British Journal of Haematology, 2008, 141, 080305033838221-???.	2.5	33
105	Mtx2 directs zebrafish morphogenetic movements during epiboly by regulating microfilament formation. Developmental Biology, 2008, 314, 12-22.	2.0	27
106	Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Research, 2008, 18, 1433-1445.	5.5	698
107	Targeted Disruption of the Basic KrÃ¼ppel-Like Factor Gene (Klf3) Reveals a Role in Adipogenesis. Molecular and Cellular Biology, 2008, 28, 3967-3978.	2.3	171
108	Erythroid Kruˆppel-Like Factor Directly Activates the Basic Kruˆppel-Like Factor Gene in Erythroid Cells. Molecular and Cellular Biology, 2007, 27, 2777-2790.	2.3	82

#	Article	IF	Citations
109	Erythroid Kruppel-like Factor Regulates the G1 Cyclin Dependent Kinase Inhibitor p18INK4c. Journal of Molecular Biology, 2007, 369, 313-321.	4.2	39
110	A global role for zebrafish klf4 in embryonic erythropoiesis. Mechanisms of Development, 2007, 124, 762-774.	1.7	50
111	In vitro differentiation of murine embryonic stem cells toward a renal lineage. Differentiation, 2007, 75, 337-349.	1.9	111
112	Genomic organisation and regulation of murine alpha haemoglobin stabilising protein by erythroid Kruppel-like factor. British Journal of Haematology, 2007, 136, 150-157.	2.5	30
113	Dynamic transcription programs during ES cell differentiation towards mesoderm in serum versus serum-freeBMP4 culture. BMC Genomics, 2007, 8, 365.	2.8	63
114	Knockdown of zebrafish crim1 results in a bent tail phenotype with defects in somite and vascular development. Mechanisms of Development, 2006, 123, 277-287.	1.7	23
115	Human KLF17 is a new member of the Sp/KLF family of transcription factors. Genomics, 2006, 87, 474-482.	2.9	97
116	A global role for EKLF in definitive and primitive erythropoiesis. Blood, 2006, 107, 3359-3370.	1.4	182
117	C/EBPÎ´Âand C/EBPÎ³ bind the CCAAT-box in the human Î²-globin promoter and modulate the activity of the CACC-box binding protein, EKLF. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1729, 74-80.	2.4	15
118	ZebrafishKLF4is essential for anterior mesendoderm/pre-polster differentiation and hatching. Developmental Dynamics, 2005, 234, 992-996.	1.8	30
119	Erythroid Kruppel-Like Factor Regulates E2F4 and the G1 Cdk Inhibitor, p18.. Blood, 2005, 106, 1357-1357.	1.4	0
120	Klf12 Is Required for Vessel Organization in Zebrafish Embryos.. Blood, 2005, 106, 3695-3695.	1.4	0
121	Zebrafish KLF4 Is Essential for Primitive Haematopoiesis.. Blood, 2005, 106, 1746-1746.	1.4	0
122	Specific Activation of Human beta-Globin Gene Expression by the Transcription Factor Ikaros.. Blood, 2005, 106, 3641-3641.	1.4	0
123	Widespread Failure of Hematolymphoid Differentiation Caused by a Recessive Niche-Filling Allele of the Ikaros Transcription Factor. Immunity, 2003, 19, 131-144.	14.3	144
124	Distinct Domains of Erythroid Kruì¨ppel-Like Factor Modulate Chromatin Remodeling and Transactivation at the Endogenous Î²-Globin Gene Promoter. Molecular and Cellular Biology, 2002, 22, 161-170.	2.3	51
125	Histone Deacetylase-Dependent Establishment and Maintenance of Broad Low-Level Histone Acetylation within a Tissue-Specific Chromatin Domainâ€. Biochemistry, 2002, 41, 15152-15160.	2.5	28
126	Human ERMAP: An Erythroid Adhesion/Receptor Transmembrane Protein. Blood Cells, Molecules, and Diseases, 2001, 27, 938-949.	1.4	24

#	Article	IF	Citations
127	Erythroid Kruppel-like factor (EKLF) coordinates erythroid cell proliferation and hemoglobinization in cell lines derived from EKLF null mice. Blood, 2001, 97, 1861-1868.	1.4	78
128	neptune, a KrÃ¼ppel-like transcription factor that participates in primitive erythropoiesis in Xenopus. Current Biology, 2001, 11, 1456-1461.	3.9	40
129	Ermap, a gene coding for a novel erythroid specific adhesion/receptor membrane protein. Gene, 2000, 242, 337-345.	2.2	31
130	An essential role in liver development for transcription factor XBP-1. Genes and Development, 2000, 14, 152-157.	5.9	430
131	Erythroid Kruppel like factor: from fishing expedition to gourmet meal. International Journal of Biochemistry and Cell Biology, 1999, 31, 1175-1192.	2.8	60
132	Erythroid KruÌ‚ppel-Like Factor Is Essential for Î²-Globin Gene Expression Even in Absence of Gene Competition, But Is Not Sufficient to Induce the Switch From Î³-Globin to Î²-Globin Gene Expression. Blood, 1998, 91, 2259-2263.	1.4	27
133	SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6881-6886.	7.1	183
134	Enrichment of blood from embryonic stem cells in vitro. Reproduction, Fertility and Development, 1998, 10, 563.	0.4	10
135	Erythroid KruÌ‚ppel-Like Factor Is Essential for Î²-Globin Gene Expression Even in Absence of Gene Competition, But Is Not Sufficient to Induce the Switch From Î³-Globin to Î²-Globin Gene Expression. Blood, 1998, 91, 2259-2263.	1.4	0
136	Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9126-9131.	7.1	165
137	Silencing of human fetal globin expression is impaired in the absence of the adult beta-globin gene activator protein EKLF.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12267-12271.	7.1	136
138	Late Relapses in Hodgkin's Disease: Are They a Distinct Entity?. Leukemia and Lymphoma, 1991, 4, 363-369.	1.3	1
139	Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8398-8402.	7.1	149
140	IMMUNE HEMOLYSIS AFTER AN ABO MISMATCHED RENAL TRANSPLANT. Australian and New Zealand Journal of Medicine, 1989, 19, 345-346.	0.5	4
141	Fulminant postsplenectomy sepsis. Medical Journal of Australia, 1988, 148, 44-46.	1.7	10